Blueprint
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 09 May
2018
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
Issued: Wednesday 9 May 2018, LSE
Simon Dingemans, Chief Financial Officer, to retire from
GSK
GlaxoSmithKline
plc (LSE/NYSE: GSK) today announces that Simon Dingemans, Chief
Financial Officer (CFO), GSK, has informed the Board of his
intention to retire from the Company and to step down from the
Board in May 2019.
The
Board will now conduct a thorough global search both internally and
externally to identify a successor.
Mr
Dingemans joined GSK in 2011 and as a member of the Board and
Corporate Executive Team (CET) has been closely involved in
developing and delivering the strategy of the Company and driving
its operational performance. As CFO, Mr Dingemans has led Finance
and a number of other Group functions, including Technology and IT,
Real Estate and Procurement.
Emma Walmsley, Chief Executive Officer, GSK, said: "Since
joining GSK, Simon has played a very significant role in shaping
the Company. He has taken a consistent and sustained approach to
support investment and improve operational efficiencies in all 3 of
our global businesses. I am particularly grateful for his support
and partnership since I took on the role of CEO and his counsel to
me as we defined our new strategy. I want to take this opportunity
to thank him for all he's done for GSK."
Simon Dingemans, Chief Financial Officer, GSK, said: "It has
been a privilege to be part of GSK and to have had the opportunity
as CFO to lead many key initiatives to drive the Company forward
and make it fitter for the future. With the new strategy set, we
have established strong foundations to deliver improved business
and financial performance and I believe now is the right time for
me to take this decision."
Philip Hampton, Chairman, GSK, said: "On behalf of the Board
I would like to thank Simon for the contribution he has made at GSK
over the last seven years. He has been a valued member of the Board
and has provided strong support and counsel to two CEOs, including
Emma during her first year in role."
Notes:
Remuneration
Mr
Dingemans is a voluntary leaver and therefore will not receive any
severance payment when he leaves the Company.
He will
continue to receive his base salary until he leaves GSK. He will
also be eligible to receive a bonus for 2018 based on a combination
of business and individual performance. Consistent with the
Company's remuneration policy and relevant long-term incentive
(LTI) plan rules approved by shareholders, as a voluntary leaver he
will not receive any bonus for the portion of 2019 for which he is
employed by GSK and any Performance Share Plan and Deferred Annual
Bonus Plan matching awards which have not already vested prior to
his departure will lapse when he leaves. In addition, he will not
be eligible to receive any further LTI awards between now and when
he leaves GSK.
GSK - a science-led global
healthcare company with a special purpose: to help people do more,
feel better, live longer. For further information please visit
www.gsk.com
GSK enquiries:
|
|
|
|
UK
Media enquiries:
|
Simon
Steel
|
+44 (0)
20 8047 5502
|
(London)
|
US
Media enquiries:
|
Sarah
Spencer
|
+1 215
751 3335
|
(Philadelphia)
|
|
|
|
|
Analyst/Investor
enquiries:
|
Sarah
Elton-Farr
|
+44 (0)
20 8047 5194
|
(London)
|
|
Tom
Curry
|
+ 1 215
751 5419
|
(Philadelphia)
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
|
|
GSK cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Principal risks and uncertainties' in the company's Annual Report
on Form 20-F for 2017.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: May
09, 2018
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|